Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Costs of Different Diabetes Treatment Technologies a

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Summary of Included Studies

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques: Biomarker Discovery, Control, Injection

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Results of the Economic Literature Review—Summary

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Calculation of Risk Reduction Owing to a Decrease in A1C Level

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques: Battery

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Costs of Different Diabetes Treatment Technologies a

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Base Case Analysis

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 1 Results a

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 2 Results

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 3 Results

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 4 Results

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Scenario 5 Results

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Continuous Glucose Monitoring Device Cost Reduction Scenarios

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Reasons for Including Four Interventions in the Primary Economic Analysis

Article Snippet: Standalone CGM + MDI (Dexcom G5 Mobile) , 2 , $0.73 , $1.46 , 4 , $0.10 , $0.40 , 4 , $0.40 , $1.60 , $3.46 , $1,263.

Techniques:

Journal: JMIR Medical Informatics

Article Title: Detecting Potential Medication Selection Errors During Outpatient Pharmacy Processing of Electronic Prescriptions With the RxNorm Application Programming Interface: Retrospective Observational Cohort Study

doi: 10.2196/16073

Figure Lengend Snippet: Ten most frequent National Drug Codes without a corresponding RxNorm concept unique identifier (n=1731).

Article Snippet: 0862-70014-01 , 22 (1.27) , Dexcom G5 mobile transmitter.

Techniques:

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Participant characteristics

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques:

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Total data collected during DG5 and EVS use and percentage of use when sensor was active

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques:

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Glycemic control during EVS and DG5 sensor use

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques: Standard Deviation